Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

Abstract: The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

Abstract: The present invention relates to compounds of the general formula IC wherein R2, R?, R?, R3, R6, X1 and X1? are as defined herein and pharmaceutically active acid addition salts thereof. Compounds of the invention are useful for the treatment of neurological and neuropsychiatric disorders.

Abstract: The polarizer comprises a layer of cholesteric liquid crystal with Grandjean structure disposed in the path of the light and in which the light in a given wavelength range is reflected with selective and circular polarization or is transmitted with reversed direction of rotation, and a mirror which reversed the direction of rotation of the circular-polarized light. The component reflected by the mirror is also transmitted. If the liquid crystal layer is concentric with the source of natural light and the mirror is spherical, the result is a source of circular polarized light. A projection system is obtained by a combination of two of the aforementioned polarizers, one serving as a polarizer and one as an analyzer, and an interposed liquid crystal display cell for modulating the intensity of the polarized light.

Abstract: Methods of and compositions for improving cardiovascular function utilizing as the active agent certain pharmaceutically acceptable salts, derivatives, isomers and homologs of lasalocid (formerly known as antibiotic X-537A) are disclosed.